Insulet Corporation
Insulet Corporation Announces Preliminary Second Quarter 2024 Revenue Results and Raises Full Year Outlook
Summary
On July 26, 2024, Insulet Corporation (NASDAQ: PODD) announced preliminary revenue results for the second quarter of 2024, reporting a 23% year-over-year increase in total revenue to $488 million. The company also raised its full-year 2024 total Omnipod revenue outlook to a range of 18% to 21%. Insulet plans to report full financial results on August 8, 2024.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement